Search Results

Two-year agreement and approximately US$198,000 in potential purchases while opening established UK first-aid, medical-supply, workplace and education channels Highlights • Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. • Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. • Poole Bay Holdings reports 20 specialist e-commerce sites and more than 30,000 products, spanning first-aid, medical, health and safety, and workplace supplies. • Poole Bay has a network of 15,000 schools across the UK, and will be providing VIVI Epi to these locations • UK Food Standards Agency research estimates approximately 2.4 million adults have a clinically confirmed food allergy, highlighting the scale of allergy-management needs [1]. • The agreement provides for launch sampling, planned promotional activity and a framework to pursue institutional and consumer channels, subject to registrations and market adoption.

Cancer Research UK’s Centre for Drug Development is using TrialAssure LINK AI to support medical writing in CRUK-sponsored studies

Biotechnology entrepreneur brings more than 25 years of life sciences and commercialization experience to Oregon’s statewide innovation initiatives.